{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:12:15Z","timestamp":1792800735236,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202006375037"],"award-info":[{"award-number":["202006375037"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901784"],"award-info":[{"award-number":["81901784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00259-024-06981-7","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T21:03:32Z","timestamp":1732568612000},"page":"1073-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical significance of quantitative assessment of right ventricular amyloid burden with [99mTc]Tc-DPD SPECT\/CT in transthyretin cardiac amyloidosis"],"prefix":"10.1007","volume":"52","author":[{"given":"Min","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Calabretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nitsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Bartko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Wollenweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Mascherbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bondermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6233","authenticated-orcid":false,"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"6981_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","volume":"98","author":"JN Dungu","year":"2012","unstructured":"Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart. 2012;98:1546\u201354.","journal-title":"Heart"},{"key":"6981_CR2","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis Cardiac Transthyretin Amyloidosis Circulation. 2016;133:2404\u201312.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"6981_CR3","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.2967\/jnumed.122.264041","volume":"63","author":"C Nitsche","year":"2022","unstructured":"Nitsche C, Mascherbauer K, Calabretta R, et al. Prevalence and outcomes of Cardiac Amyloidosis in All-Comer referrals for bone scintigraphy. J Nucl Med. 2022;63:1906\u201311.","journal-title":"J Nucl Med"},{"key":"6981_CR4","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","volume":"149","author":"A Porcari","year":"2024","unstructured":"Porcari A, Fontana M, Canepa M, et al. Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in Transthyretin Amyloid Cardiomyopathy. Circulation. 2024;149:1157\u201368.","journal-title":"Circulation"},{"key":"6981_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, et al. Multicenter Study of Planar Technetium 99m pyrophosphate Cardiac Imaging: Predicting Survival for patients with ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016;1:880\u20139.","journal-title":"JAMA Cardiol"},{"key":"6981_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","volume":"18","author":"DF Hutt","year":"2017","unstructured":"Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18:1344\u201350.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"6981_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s12350-016-0768-9","volume":"25","author":"MN Vranian","year":"2018","unstructured":"Vranian MN, Sperry BW, Hanna M, et al. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: associations with echocardiographic disease severity and outcomes. J Nucl Cardiol. 2018;25:1247\u201356.","journal-title":"J Nucl Cardiol"},{"key":"6981_CR8","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799\u2013806.","journal-title":"Eur Heart J"},{"key":"6981_CR9","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s12350-020-02455-z","volume":"28","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Ando Y, Bokhari S, et al. Addendum to ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021;28:1769\u201374.","journal-title":"J Nucl Cardiol"},{"key":"6981_CR10","doi-asserted-by":"crossref","unstructured":"Rettl R, Mann C, Duca F et al. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging 2021.","DOI":"10.1093\/ehjci\/jeab226"},{"key":"6981_CR11","unstructured":"Accurate. reproducible, and standardized quantification. xSPECT Quant White Paper: Siemens Healthineers.2018."},{"key":"6981_CR12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"6981_CR13","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065\u2013123.","journal-title":"J Nucl Cardiol"},{"key":"6981_CR14","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s12350-019-01893-8","volume":"27","author":"F Caobelli","year":"2020","unstructured":"Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative (99m)Tc-DPD SPECT\/CT in patients with suspected ATTR cardiac amyloidosis: feasibility and correlation with visual scores. J Nucl Cardiol. 2020;27:1456\u201363.","journal-title":"J Nucl Cardiol"},{"key":"6981_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/13506129.2012.684810","volume":"19","author":"O Leone","year":"2012","unstructured":"Leone O, Longhi S, Quarta CC, et al. New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. Amyloid. 2012;19:99\u2013105.","journal-title":"Amyloid"},{"key":"6981_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","volume":"7","author":"JN Dungu","year":"2014","unstructured":"Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7:133\u201342.","journal-title":"JACC Cardiovasc Imaging"},{"key":"6981_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jcmg.2017.06.020","volume":"11","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Vranian MN, Tower-Rader A, et al. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. JACC Cardiovasc Imaging. 2018;11:234\u201342.","journal-title":"JACC Cardiovasc Imaging"},{"key":"6981_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ejhf.2113","volume":"23","author":"V Castiglione","year":"2021","unstructured":"Castiglione V, Franzini M, Aimo A, et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. Eur J Heart Fail. 2021;23:217\u201330.","journal-title":"Eur J Heart Fail"},{"key":"6981_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, et al. Natural history of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification using a Novel Staging System. J Am Coll Cardiol. 2016;68:1014\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"6981_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ejechocard\/jer289","volume":"13","author":"F Cappelli","year":"2012","unstructured":"Cappelli F, Porciani MC, Bergesio F, et al. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging. 2012;13:416\u201322.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"6981_CR21","doi-asserted-by":"crossref","unstructured":"Porcari A, Fontana M, Canepa M et al. Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy. Circulation. 2024.","DOI":"10.1161\/CIRCULATIONAHA.123.066524"},{"key":"6981_CR22","doi-asserted-by":"crossref","unstructured":"Wollenweber T, Rettl R, Kretschmer-Chott E et al. In vivo quantification of myocardial amyloid deposits in patients with suspected transthyretin-related amyloidosis (ATTR). J Clin Med 2020;9.","DOI":"10.3390\/jcm9113446"},{"key":"6981_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2967\/jnumed.120.247312","volume":"62","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Park MA, Cuddy S, et al. Absolute quantitation of Cardiac (99m)Tc-Pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT. J Nucl Med. 2021;62:716\u201322.","journal-title":"J Nucl Med"},{"key":"6981_CR24","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s12350-015-0261-x","volume":"23","author":"A Castano","year":"2016","unstructured":"Castano A, DeLuca A, Weinberg R, et al. Serial scanning with technetium pyrophosphate ((99m)Tc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol. 2016;23:1355\u201363.","journal-title":"J Nucl Cardiol"},{"key":"6981_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316.","journal-title":"N Engl J Med"},{"key":"6981_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","volume":"8","author":"MS Maurer","year":"2015","unstructured":"Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519\u201326.","journal-title":"Circ Heart Fail"},{"key":"6981_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2967\/jnumed.122.265352","volume":"64","author":"M Papathanasiou","year":"2023","unstructured":"Papathanasiou M, Kessler L, Bengel FM, et al. Regression of myocardial (99m)Tc-DPD uptake after Tafamidis Treatment of Cardiac Transthyretin Amyloidosis. J Nucl Med. 2023;64:1083\u20136.","journal-title":"J Nucl Med"},{"key":"6981_CR28","unstructured":"Rettl R, Calabretta R, Duca F et al. Reduction in (99m)Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy. Amyloid 2023:1\u201310."},{"key":"6981_CR29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","volume":"24","author":"R Rettl","year":"2023","unstructured":"Rettl R, Wollenweber T, Duca F, et al. Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24:1019\u201330.","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06981-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06981-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06981-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:27:28Z","timestamp":1737502048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06981-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6981"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06981-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Vienna General Hospital, Medical University of Vienna Institutional Review Board (EK1557\/2020) for retrospective analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All other authors have no relationships relevant to the contents of this paper to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}